Jessica is a senior editor, contributing most frequently to daily pharmaceutical coverage in Scrip and Pink Sheet. With a lengthy career covering the pharmaceutical sector, she specializes primarily in business and commercial news, launch strategy, M&A and market access issues.
Latest from Jessica Merrill
Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.
Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.
Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback
CEO Matt Gline talked to Scrip in an interview about dealmaking and the road back to commercialization.
Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.
The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.